Menses - PMS
●更年期不定愁訴と抗不安薬[日薬理誌 115(1),21-28(2000)]
鳥居塚和生、溝脇 万帆、花輪 壽彦(北里研究所東洋医学総合研究所臨床研究部)
要約:
更年期不定愁訴は多彩で個人差も大きいが，のぼせ，ほてり，冷え性など身体的愁訴のほか，精神面では不安感，憂鬱，不眠などといった症状を呈する．閉経前後では卵巣機能の低下によりエストロゲンの分泌が低下し，視床下部からのGnRH や下垂体前葉からの卵胞刺激ホルモンなどの過剰分泌が起こる。 この過剰分泌による調節機能の障害が自律神経に異常をきたし更年期障害の諸症状がもたらされると考えられている．
性ホルモンが精神症状に及ぼす影響については，いまだに不明な点も多いが，女性においては性ホルモンのバランスが大きく変化する月経前，産褥期，更年期といった３つの時期に，月経前症候群（PMS），月経前不快気分障害（PMDD），マタニティーブルー，更年期不定愁訴など気分障害関連の症状を呈することが多い。
その最も重症な時期においては，不安を伴う中等症程度のうつ状態を呈すこともあり，日常の社会生活に支障をきたすこともある。
プロゲステロン代謝物をはじめとしたステロイド類の一群はニューロステロイドと呼ばれ，GABAA 受容体に結合することから気分障害や性行動，ストレス反応など情動反応への寄与が考えられている。 脳内のニューロステロイドは性周期，妊娠，ストレス，性行動，記憶や加齢などの過程において生理的に神経伝達修飾作用を行っていると推定できる．未解決の部分が多くあるが，性ホルモン，ニューロステロイドなどは中枢神経系に作用しその機能を調節する役割を担っていると考えられる．
融 道男 東京医科歯科大学教授・神経精神科
--------------------------------------------------
●新しい抗精神病薬
精神分裂病の治療薬（抗精神病薬）は現在30種ほどあるが，1996年６月からリスペリドンがこれに加わった。
これまでの抗精神病薬はほとんどすべてドパミンＤ鯤受容体遮断薬であったが，この新薬は，SDA（セロトニン・ドパミン・アンタゴニスト）と呼ばれ，強力なセロトニン5HT2A受容体拮抗作用と，ハロペリドールに匹敵する抗ドパミンＤ鯤作用をあわせもつという特徴がある。
抗Ｄ鯤作用による従来の抗精神病効果に加え，強い抗5HT2A作用により錐体外路性副作用が起こりにくく，陰性症状に対する効果が期待されている。
発売以来全国的に広く使われるようになり，経験も多く寄せられるようになった。 それによると，リスペリドンはたしかに錐体外路症状の発現が弱く，特に4mg／日以下では抗Parkinson薬の併用は不要であるという。
リスペリドンに変更して抗Parkinson薬の併用を減らすことができたという報告もある。 抗精神病薬のやっかいな副作用の一つに精神機能の抑制があり，特に病状が軽くなってくると頭が重いとか頭が働かないなどの訴えが増えてくる。 このような症例でリスペリドンを従来の抗精神病薬に置換すると，精神機能が活発になり，Ｄ鯤遮断作用もあるので再発予防の役割も果たすことになる。 精神分裂病の治療は長期にわたることが多いので，副作用の軽減によりコンプライアンスがよくなり，患者のQOLが向上することも期待される。
●さかんな遺伝子研究
どの臨床科でも似た状況にあると思うが，精神疾患の遺伝子研究がさかんに行われるようになった。
1997年３月に開かれた第19回日本生物学的精神医学会では分子遺伝学的研究の演題が全演題の20％を占めており，うち２／３は精神疾患の遺伝子変異を探索する研究であった。
どの会場もたくさんの人を集め，質疑も活発であった。
精神分裂病を対象とした研究は11題，気分障害７題，アルコール依存症５題などが中心で，ほとんどが関連研究で，明快なポジティブ・データはなかった。 精神疾患は家系内集積を示し，遺伝的な負因が発症に関与することは推定されるが，遺伝性神経疾患などと異なり，遺伝様式がMendelの法則に従わないので，多くの遺伝子が関与している疾患であると考えられてきた。
特に一卵性双生児の一致率が精神分裂病でも気分障害でも50％前後とされるので，環境因子の関与や脆弱性という概念が導入されている現状である。 このような複雑遺伝をする精神疾患を解明する道は，糖尿病やAlzheimer病で行われているように，多くの病因の異なる疾患が包括されていることを想定し，単一遺伝子が関与している（Mendel遺伝型）疾患を見出し，独立させることから始まるのではなかろうか。 例えばCATCH22症候群という，心血管奇形，特異な顔貌，胸腺低形成，口蓋裂，副甲状腺機能低下病（低カルシウム血症）などを呈する症候群が，22q11.21-q11.23に小欠失があることが知られているが，ときに精神症状により精神分裂病と誤診されることもある。 この近傍にはカテコラミンの代謝酵素であるカテコール-Ｏ-メチル基転移酵素の遺伝子もあるので重要な検索部位であろう。 精神疾患を表現型とする単一遺伝疾患を取り除き，その遺伝子座位近傍をプローブとした連鎖解析などが，特定の家系についてなされることが難攻不落の精神疾患の病因解明の一つの攻め方ではなかろうか。
今日の治療指針1998年版/(C)1998 IGAKU-SHOIN Tokyo
USA TODAY Feb. 18, 2000
By A.J.S. Rayl
With medical adviser Jonathan M. Sackier, M.D.
First described as a true medical disorder in 1931 by American gynecologist Dr. T. Frank, PMS has only recently become the focus of considerable research. New findings have prompted the creation of the new classification - premenstrual dysphoric disorder (PMDD) - to differentiate the more acute manifestations of the condition.
★PMS/PMDD symptoms
PMS is characterized by a constellation of more than 100 physical and emotional symptoms that occur during the phase in the female cycle directly preceding menstruation.
Some PMS symptoms[略]
★PMDD symptoms
"The main symptoms we look at for PMDD are what are known as the core symptoms of depression -irritability, anxiety and mood lability (mood swings)" says Dr. Catherine A. Roca, staff psychiatrist in the behavioral-endocrinology branch at the National Institute on Mental Health (NIMH) in Bethesda, Md.
Other symptoms include decreased interest in daily activity, difficulty concentrating, decreased energy, sleep disturbances, appetite changes - such as food cravings for chocolate, salt, carbohydrates - in addition to the general PMS physical symptoms above.
★Incidence
Estimates vary as to how many women suffer and how much they suffer at "that time of the month."
"We actually have women who don't have any physical symptoms, who serve as our controls in studies," says Roca. "They may have some cramps or very mild symptoms," she says, "but none of the depression, irritability or anxiety that you see in PMS or in the severe form of PMDD."
Most estimates hold that 70-90% of women experience premenstrual symptoms at some point during their childbearing years. Of this group, an estimated 30-40% have PMS, with symptoms debilitating enough to interfere at least somewhat with daily living activities. Only 3-7% of women have PMDD, according to Roca.
★Diagnosis[略]
★Cause[略]
★Treatment
[略]
Calcium , Vitamin B6, Vitamin E, Tryptophan
Other medications - NSAIDS, Female sex hormones estrogen and progesterone, SSRIs, Leupron
Contents of this page:
General/Overviews
Anatomy/Physiology
Clinical Trials
Diagnosis/Symptoms
Research
Specific Conditions/Aspects
Treatment
Organizations
Children
Teenagers
The primary NIH organization for research on Menstruation and Premenstrual Syndrome is the
National Institute of Child Health and Human Development
Search MEDLINE for recent research articles on
Menstruation and Premenstrual Syndrome:
・ Menstrual Cycle
・ Menstrual Disorders
・ Premenstrual Syndrome
You may also be interested in these MEDLINEplus related pages:
・ Menopause
・ Women's Health
●General/Overviews
Menstruation: A Parents' Guide for Preparing Daughters (Mayo Clinic, Mayo Foundation for Medical Education and Research)
Premenstrual Syndrome (National Women's Health Information Center)
Premenstrual Syndrome: Period Before your Period (Mayo Clinic, Mayo Foundation for Medical Education and Research)
Understanding Menstruation (Nemours Foundation)
●Anatomy/Physiology
Women's Sex Hormones - A Refresher Course (Mayo Foundation for Medical Education and Research)
●Clinical Trials
ClinicalTrials.gov: Amenorrhea (National Institutes of Health)
ClinicalTrials.gov: Menstruation Disturbances (National Institutes of Health)
ClinicalTrials.gov: Premenstrual Syndrome (National Institutes of Health)
ClinicalTrials.gov: Shock, Septic (National Institutes of Health)
Clinical Trials: Dysmenorrhea (CenterWatch, Inc.) - industry-sponsored clinical trials
Clinical Trials: Menstrual Disorders (CenterWatch, Inc.) - industry-sponsored clinical trials
Clinical Trials: Premenstrual Syndrome (CenterWatch, Inc.) - industry-sponsored clinical trials
●Diagnosis/Symptoms
Menstrual Cycle Problems: Self-Care Flowcharts (American Academy of Family Physicians)
●Research
How Women Perceive Menstruation and Their Menstrual Patterns (World Health Organization)
●Specific Conditions/Aspects
Amenorrhea - When Menstruation Goes Away (Mayo Foundation for Medical Education and Research)
Menstrual Cramps (Dysmenorrhea) (MedicineNet, Inc.)
Premenstrual Dysphoric Disorder (PMDD) (Society for the Advancement of Women's Health Research)
Tampon Safety: TSS Now Rare, but Women Still Should Take Care (Food and Drug Administration)
Tampons and Asbestos, Dioxin, and Toxic Shock Syndrome (Food and Drug Administration)
●Treatment
Endometrial Ablation Alternative to Hysterectomy (National Women's Health Information Center)
●Organizations
American College of Obstetricians and Gynecologists
National Institute of Child Health and Human Development
●Children
All About Menstruation (Nemours Foundation)
Talking to Your Child About Menstruation (Nemours Foundation)
●Teenagers
All About Menstruation (Nemours Foundation)
Coping with Common Period Problems (Nemours Foundation)
Last updated: 01 February 2001
Think It's PMS?
Think again ...
It could be PMDD.
If intense mood and physical symptoms interfere with your day to
day activities and relationships the week before your period, you
could have what doctors recognize as PMDD (Premenstrual
Dysphoric Disorder). The good news is there is treatment available
that can help you feel more like the woman you are every day of
the month.
What is PMDD?
Could I have PMDD?
Can Sarafem help?
Questions to ask your doctor
Sarafem - The full prescribing information
Information for the patient[患者向け服用ガイド] -READ THIS INFORMATION COMPLETELY BEFORE USING SARAFEM
One in eight Americans,or 12.5%of the U.S.population,suffers from depression.
It often interferes with everyday life and can affect those closest to the sufferer.
But there is good news! Depression can be treated and managed successfully. Even
people with severe depression can lead productive lives, but many people don't
know enough about depression to recognize the symptoms,or they don't realize
that it is treatable. The information on this Web site is intended to answer your
questions regarding depression and ensure that you have the facts that matter.
Disease information
About Prozac
Taking control
Recovery tools
Caring for others
Community
Prozac in the news
Survey
Visitor poll
Safety
Product label
, Search , Sitemap
月経前症候群(PMS)
| [1096]●製品 Fluoxetine HC1 (Sarafem Capsules[Lilly]) |
日本語版註）fluoxetine HCl (Sarafem [Lilly→Warner Chilcott])
【別名】 【開発元】Eli Lilly [DBR_ID]15906-117B
【化学名】(±)-N-methyl-3-phenyl-3-[(α,α,α-trifluoro-ptolyl)oxy]propylamine hydrochloride
【承認〜カプセル】FDA申請=(再)21-Jan-2000、FDA諮問委勧告=3-Nov-99、FDA承認=6-Jul-2000、発売=Aug 2000; 【承認〜錠】FDA申請=19-May-2005、FDA承認=19-May-2006 【製剤】Pulvules(Capsules) - fluoxetine HCl EQ 10mg,20mg fluoxetine; Tablets -fluoxetine HCl EQ 10mg,15mg,20mg fluoxetine
【適応】(月経前不快気分障害)indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adult women (18 years and older).
【用法用量】20mg1日1回 【作用】fluoxetineのPMDDにおける作用機序は不明だが、セロトニン取り込み阻害に関連すると考えられる。 【特徴】 【製品情報】Sarafem 【添付文書】Sarafem Caps-PI Sarafem Tabs-PI 【提携】 【EU】
【日本】未開発 【その他】Warner Chilcott, Inc.が2003.1 SarafemをEli Lillyより米国販売権取得
●15906-117B
FLUCTIN;FLUOXEREN;FLUOXETINE HCL[INN][USAN];FLUOXETIN-RATIOPHARM;FONTEX[;LILLY-DK];LILLY 110140;PROZAC LIQ.;PROZAC;塩酸フルオキセチン;フルオキセチン塩酸塩;プロザック;ロバン
《JA》PROZAC（聖マリアンナ医科大学）IN IU＊‖《US》PROZAC（DISTA PRODUCTS CO{DIV EL）01-88＊‖PROZAC LIQ.（DISTA PRODUCTS CO{DIV EL）09-91＊‖PROZAC（ELI LILLY & CO）11-96＊FDA=961121‖《UK》PROZAC（DISTA PRODUCTS CO{DIV EL）01-89＊‖《FR》PROZAC（ELI LILLY & CO）02-90＊‖《WG》FLUCTIN（ELI LILLY & CO）04-90＊‖FLUCTIN（HOECHST AG）04-90＊‖FLUOXETIN-RATIOPHARM（RATIOPHARM）12-96＊‖《IT》PROZAC（ELI LILLY & CO）12-88＊‖FLUOXEREN（MENARINI）04-89＊
●2004.5.1 以降 Drugs@FDA
Drug Name(s) =SARAFEM (FLUOXETINE HYDROCHLORIDE)
FDA Application No. =NDA # 018936
Active Ingredient(s)=FLUOXETINE HYDROCHLORIDE
Company =LILLY
Dosage Form/Route =CAPSULE; ORAL: EQ 10MG BASE; EQ 20MG BASE
Strength =
- Approval Date=07/06/2000[058][New or Modified Indication]:Label[添付文書]|Letter[承認書]|SARAFEM
申請January 21, 2000(SARAFEM (fluoxetine hydrochloride) Pulvulesの再申請)
/追加適応=the use of fluoxetine in the treatment of PMDD(premenstrual dysphoric disorder).
- Approval Date=06/12/2002[067][New Dosage Regimen]:Label[添付文書]|Letter[承認書]|
申請March 21, 2001(SARAFEM (fluoxetine hydrochloride) CAPSULE)
/追加適応=for the use of Sarafem in the treatment of premenstrual dysphoric disorder
(PMDD), using an intermittent dosing regimen, as an alternative to the currently approved
continuous dosing regimen
FDA Application No. =NDA # 021860
Active Ingredient(s)=FLUOXETINE HYDROCHLORIDE
Company =WARNER CHILCOTT
Dosage Form/Route =TABLET; ORAL: EQ 10MG BASE; EQ 15MG BASE; EQ 20MG BASE
Strength =
- Approval Date=05/19/2006[000][Approval]:Label[添付文書]|Letter[承認書]|
申請May 19, 2005
適応 for the treatment of premenstrual dysphoric disorder.
Original Approval or Tentative Approval Date May 19, 2006
Chemical Type 3 New formulation
Review Classification S Standard review drug
情報ソース●Drug Approval part4(P-S)
Sarafem (Fluoxetine HC1) Capsules, Rx
Lilly
NDA 18-936/SE1-058
7/6/00 July-6-2000 |7/6/00承認書 |7/6/00添付文書
Sarafem Indications: Premenstrual Dysphoric Disorder (PMDD).
★2008/8/15/
Appl
No | TE Code | RLD | Active
Ingredient | Dosage Form;
Route | Strength | Proprietary
Name | Applicant | 承認日 | 先発権 | 特許 | 備考 |
|---|
| 018936 | AB2 | No | FLUOXETINE HYDROCHLORIDE | CAPSULE; ORAL | EQ 10MG,20MG BASE | SARAFEM | LILLY | Jul 6, 2000 | | | |
| 021860 | | No | FLUOXETINE HYDROCHLORIDE | TABLET; ORAL | EQ 10MG,15MG,20MG BASE | SARAFEM | WARNER CHILCOTT | May 19, 2006 | - | - | |
●Products
★Sarafem
2003.1 Sarafem (fluoxetine hydrochloride) PMDD治療薬をEli Lillyより米国販売権取得(2002売上$80 million)。
■Investor Relations
●News[2006/1〜]
Operating Results End of Year 2005[pdf;2006.3.28]
FDA Approves Taclonex(R)[pdf,2006.1.10]
●Quarterly Results
Operating Results End of Year 2005[pdf,10p;200006.3.28]
●Annual Reports
Annual Report 2007
Annual Report 2006
●SEC Filings
10-K annual report Warner Chilcott Limited[2007.2.29]
10-K annual report Warner Chilcott Limited[2007.3.26]
Form 424B3 Prospectus Filed Pursuant to Rule 424[2006.4.25]
●Press Release[2003/5-2004/10]
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007[2008.2.13] - [pdf]
Operating Results End of Year 2005[2006.3.28] - [pdf]
Warner Chilcott PLC Announces strong results for the fourth quarter ended 30 September 2004[2004.10.27]
Galen Holdings PLC Name Change to Warner Chilcott PLC[2004.6.25]
- 北米事業への主体移行により、社名変更。
FDA TALK PAPER July 6, 2000
FDA has approved fluoxetine (Sarafem) as the first drug treatment for Premenstrual Dysphoric Disorder(PMDD), a disorder that causes mood changes and physical symptoms such as bloating and breast tenderness in women. Fluoxetine was approved as Prozac in December l987 for treating depression, and has also been approved for treating obsessive compulsive disorder and bulimia. The following may be used to respond to questions.
On November 3, 1999, FDA's Psychopharmacologic Advisory Committee unanimously recommended approval for fluoxetine to treat women with PMDD. The committee concluded that fluoxetine was effective for the condition and that PMDD has well defined, accepted diagnostic criteria. The committee also advised that the drug should be used only to treat women whose symptoms are severe enough to interfere with functioning at work or school, or with social activities and relationships.
According to the American Psychiatric Association Diagnostic and Statistical Manual (DSM-IV), a diagnosis of PMDD requires that patients experience at least five of the symptoms that characterize PMDD. PMDD has both affective (mood) and physical symptoms, and is characterized by depressed mood, anxiety, tension, affective lability (a tendency to alternate between cheerful and somber moods), and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite, headache, joint and muscle pain. The mood symptoms often cause disturbances in social relationships. Physical symptoms include weight gain, bloating, and breast tenderness. To support a diagnosis of PMDD, the symptoms must occur regularly in the luteal phase of a woman's cycle, and disappear after onset of menstruation. (The luteal phase corresponds to the period between ovulation and onset of menstruation.)
Fluoxetine's effectiveness for the treatment of PMDD was established in two double-blind placebo-controlled trials. In the first study, 320 patients were given fluoxetine continuously throughout the menstrual cycle. This study showed that the drug was significantly more effective than placebo by measurements of changes in mood and physical symptoms of PMDD. In a second study, 19 patients were treated with fluoxetine and placebo continuously throughout the menstrual cycle for a period of three months each. In this study, fluoxetine was significantly more effective than placebo on a scale measuring changes in mood, physical and social impairment symptoms.
Sarafem will be marketed by Eli Lilly, of Indianapolis, Ind., with a patient information brochure and physician labeling specific for the drug's use. The drug was not studied in women who were taking oral contraceptives. Common side effects were similar to those experienced by other fluoxetine users and included nausea, tiredness, nervousness, dizziness and difficulty concentrating.
Psychiatric News December 3,1999
Surveys indicate that from 3 percent to 8 percent of North American women in their reproductive years suffer from premenstrual dysphoric disorder (PMDD).
The Food and Drug Administration's (FDA's)Psychopharmacologic Drugs Advisory Committee has recommended that the FDA approve an indication for fluoxetine (Prozac)in the treatment of PMDD.
On November 3 Prozac-manufacturer Eli Lilly and Company announced the advisory panel's unanimous recommendation.The FDA rarely rejects the advisory panel's recommendations,,and if approved,Prozac will be the first drug specifically indicated for PMDD.
Psychiatric News August 18,2000
Whether and where premenstrual dysphoric disorder should be included in DSM has been controversial for nearly 15 years. Now the debate has taken a new twist with recent actions taken by the federal government.
Through the development of both DSM-III-R and DSM-IV, the validity of premenstrual dysphoric disorder (PMDD) as a distinct,diagnosable condition has been intensely debated. Now the U.S. Food and Drug Administration has weighed in with its own position. Last month the agency accepted PMDD as a valid indication for pharmacologic therapy and approved fluoxetine for its treatment.
The decision nearly 15 years ago by the DSM-III-R Task Force to include PMDD, then referred to as "late luteal phase dysphoric disorder,"in Appendix A,"Proposed Diagnostic Categories Needing Further Study,"rather than as an officially approved diagnostic category,was one of intense discussion and controversy.
[略]
The PMDD Work Group recommended that the DSM-IV Task Force keep the disorder in Appendix A.
★FDA Accepts PMDD
The federal government now says it's convinced of what the DSM experts had determined in 1993 needed further study.
The FDA's regulations for the labeling of a drug for a specific indication require that the condition be recognized and accepted in the clinical setting and identified and defined unambiguously,that appropriate methods be used in assessment and measurement of the condition,and that clinical trials show efficacy and safety for the proposed pharmacotherapy.
Both researchers and clinicians see the FDA's approval of PMDD as a message to patients and clinicians that PMDD is a distinct clinical entity and that accepted,proven treatments exist. As work on DSM-V gets under way,the relevant work groups and task force will undoubtedly have to address the question again.
Jean Endicott,Ph.D.,a professor of clinical psychology in the department of psychiatry at Columbia University and chief of the department of research,assessment,and training at the New York State Psychiatric Institute,believes that the task force's debate will be easier to resolve because of the FDA decision.Endicott testified before the FDA Advisory Panel that recommended approval of the new indication.
★Round-Table Review[略]
★Revisiting DSM Inclusion[略]
★DSM Research Criteria Successful[略]
★Marketing Sarafem
The FDA's approval of fluoxetine for PMDD, under the new trade name Sarafem,was requested by Eli Lilly and Co.
Lilly's best - selling fluoxetine product,sold since 1987 under the trade name Prozac,will lose patent protection in 2003. Both U.S.and global sales of Prozac have been declining recently. Lilly claims the cause is stiff competition in the SSRI market,but the drop also may be due to unfavorable press accounts of potential adverse drug reactions linked to Prozac (Psychiatric News,August 4.)
The company is currently overseeing clinical trials of fluoxetine-R,a chemical isomer that it hopes will have an improved safety profile.
Lilly says that the renaming of fluoxetine as Sarafem will "help with educational efforts for this largely underrecognized disorder while reducing confusion about the differences between depression and PMDD."
PMDD, estimated to affect 3 percent to 5 percent of menstruating women in the United States,could provide a significant new market to boost sales.And the global treatment market is also expanding.
According to Endicott,the diagnosis of PMDD is now an accepted indication for treatment in at least 16 countries,including the United Kingdom (which should lead to approval for the entire European Union),New Zealand,and Australia.
Lilly has many critics over its decision to change the Prozac name. "It erodes the trusting relationship between the doctor and the patient," said Nada Stotland,M.D.,chair of psychiatry at Illinois Masonic Medical Center, a professor of psychiatry and obstetrics and gynecology at Rush Medical College, and speaker-elect of the APA Assembly.
"Why change the name?"asked Stotland,who also served on the PMDD Work Group,in an interview with Psychiatric News. "People shouldn't be ashamed of taking Prozac; this simply feeds into the prejudice against psychiatry and against psychoactive drugs.Is an internist or gynecologist who is most likely to see these patients 揚oing to have time to explain to women that this is the same thing as Prozac?"
Stotland, an expert on women's issues in psychiatry,,has been critical of PMDD as a formal diagnosis because of her concerns for the methodological problems,as well as the lack of research concerning the social aspects of the disorder.
"So far,biomedicine has ignored the social medicine aspects of PMDD, "Stotland told Psychiatric News."Psychiatry is supposed to be both."
Stotland also is concerned that with a new medication approved to treat women with PMDD, some clinicians may be quick to prescribe without going through the rigorous workup,including prospective daily ratings,necessary to diagnose the disorder accurately and appropriately.
★More Accessible,Higher Quality Care
[略]
株式会社メドレット
Medlet Japan KK
〒103-0024 東京都中央区日本橋小舟町１２−１０共同ビル（掘留）５Ｆ 久永&Co気付
tel.03-3664-2020 fax.03-3666-3188 URL:www.medmk.com/mm/ E-Mail: support@medmk.com
- 一覧へ戻る。
- ホームへ戻る。
- -------------------------------------------------
- 1096★17/02★01.01.22★005★月経前不快気分障害治療薬フルオキセチン（Sarafem）/2p●月経前不快気分障害(PMDD)，月経前症候群(PMS)[42KB]
- -------------------------------------------------
- 1081★16/13★00.06.26★056★St.John's wortの薬物相互作用/1p●1081追加メモ[70KB]
- 1086★16/18★00.09.04★080★新しい長時間作用型メチルフェニデート(Concerta)|
●1086追加メモ:注意欠損多動性障害（ADHD:attention deficit/hyperactivity disorder）治療薬[25KB]
- 1094★16/26★00.12.11★114★精神疾患に対するバルプロ酸塩およびその他の抗痙攣薬/2p|●1089追加メモ:抗てんかん剤[269KB]
- -------------------------------------------------
- 1049★15/07★99.03.26★030★ナルコレプシ−治療薬モダフィニル/2p●1049追加メモ[153KB]
- 1050★15/08★99.04.09★033★抑うつ及び不安に対する薬剤/6p●1050追加メモ[604KB]
- -------------------------------------------------
- 1041★14/25★98.12.04★113★うつ病に対するシタロプラム/2p●1041追加メモ
- -------------------------------------------------
- 1007★13/17★97.08.15★077★禁煙に対するブプロピオン（ZYBAN）
- 1014★13/24★97.11.21★107★ST. JOHN'S WORT/2p●1014追加メモ
- -------------------------------------------------
- 0990★12/26★96.12.20★113★ミルタザピン−新しい抗うつ剤
- -------------------------------------------------
- 0942★11/04★95.02.17★013★強迫疾患に対するフルボキサミン
- 0946★11/08★95.04.14★033★うつ病に対するネファゾドン
- -------------------------------------------------
- 作成：2001.3.8 最終更新:2008.8.17 小菅博之
The Medical Letter日本語版
●追加メモ to 1096
On Drugs and Therapeutics
- このページは［The Medical Letter日本語版］の補足データとして添付しています。 ［The Medical Letter］は新薬の厳正な評価誌であり、ここに収録される製品は新しくＦＤＡ承認された新薬に対する評価を中心としています。
- 企画意図の第一は、収録製品についての米国内・世界での背景情報です。 例えば、各製品の承認関連データ、競合品との、あるいは市場での位置づけ、疫学データなど。 第二は、日本での該当製品や市場の情報。 市場の主要製品売上、開発中の治験薬等。 調査項目としては、■製品■解説■データ■臨床ガイドラインなど■総説記事・文献■ニュース・トピックス■リンク■主要サイト